



CONQUERING COMPLEX STUDIES:
Accelerating Patient Recruitment in
Ranibizumab Study for Retinopathy
of Prematurity in Preterm Infants



STUDY OVERVIEW:


Lambda Therapeutic Research successfully conducted a phase-4 study to assess the safety and efficacy of ranibizumab in treating retinopathy of prematurity (ROP), a condition affecting the eyes of premature infants, in India. This study aimed to enroll 50 patients with ROP.

INCLUSION CRITERIA:

Preterm infants with gestational age at birth ≤ 32 weeks OR birth weight ≤ 1500 g and weight at baseline ≥ 800 gm.

Treatment naïve patients with ROP

Given the vulnerability of preterm infants to higher mortality rates and poorer quality of life, the study balanced the quality of care with the clinical trial requirements.



APPROACH:

Strategic Site Selection:

Selected study sites capable of providing the standard of care required for these preterm infants with ROP.

Patient Engagement:

Regular communication with investigators and site teams throughout the study. This proactive approach aimed to minimize dropouts and ensure strict adherence to the treatment protocol.

Comprehensive Training:

Comprehensive training programs were implemented across all study sites to guarantee the implementation of safety measures on a daily basis. This step was critical in safeguarding the well-being of the enrolled infants and maintaining the integrity of the study.



OUTCOME:

Lambda's meticulous approach achieved efficient trial execution, **successfully enrolling 50 preterm infants with ROP in just 2.5 months**, across six sites. This case study highlights Lambda's ability to navigate the complexities of patient recruitment in a sensitive population, demonstrating a robust




Connect with our experts at **Email: BD@lambda-cro.com**
to leverage the extensive end-to-end capabilities of Lambda & Novum.

EXTENSIVE EXPERIENCE

Lambda Therapeutic Research has vast experience of conducting **7500+** clinical studies including **PK-PD studies, Biosimilar PK-PD & Immunogenicity Studies, Nutraceuticals & Consumer Product studies and Phase-I studies.**

700+ BEDS GLOBALLY



Connect with our experts at Email: BD@lambda-cro.com
to leverage the extensive end-to-end capabilities of Lambda & Novum.